Health Trials

Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation

ConditionLung Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChang Chen

About this trial

By establishing a prospective, multicenter lung transplantation clinical cohort, this study aims to systematically evaluate the utility of cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomics in monitoring and predicting graft dysfunction after lung transplantation, and to develop a multi-omics predictive model for early identification, dynamic monitoring, and mechanistic investigation of acute lung allograft dysfunction (ALAD) and chronic lung allograft dysfunction (CLAD).

Eligibility criteria

Qualifiers

Recipients aged ≥18 years undergoing single or double lung transplantation;

Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study;

Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations;

Recipients able to undergo dynamic pulmonary function monitoring during follow-up;

Disqualifiers

History of active malignancy or presence of untreated malignancy within 5 years prior to transplantation;

Presence of active systemic infection or significant immune rejection;

Female patients who are pregnant or lactating;

Any other condition deemed by the investigator to be inappropriate for inclusion .

Trial design

Treatments tested in this trial

  • longitudinal changes in multi-omics profiling of peripheral blood

Treatment groups

No treatment groups listed

Sponsors and collaborators

Chang Chen

Lead sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Sponsor institution

Source ClinicalTrials.gov